Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118752 | 0.91 | KDR (0.46) | FGFR1KDRPDGFRBEGFRSRC | |
| SCHEMBL2114117 | 0.84 | KDR (0.46) | FGFR1KDRPDGFRBEGFRSRC | |
| SCHEMBL2115512 | 0.82 | KDR (0.49) | FGFR1KDRPDGFRBEGFRSRC | |
| SCHEMBL7009166 | 0.81 | KDR (0.37) | FGFR1KDRPDGFRBEGFRSRC | |
| SCHEMBL2114389 | 0.79 | FLT3 (0.41) | FGFR1KDRPDGFRBEGFRCHEK1 | |
| SCHEMBL2116248 | 0.79 | KDR (0.40) | FGFR1KDRPDGFRBEGFRCHEK1 | |
| SCHEMBL394231 | 0.79 | FLT3 (0.50) | KDRPDGFRBFLT3KITFLT4 | |
| SCHEMBL2115891 | 0.78 | MEN1 (0.48) | FGFR1KDRPDGFRBEGFRKIT | |
| SCHEMBL2113945 | 0.78 | LRRK2 (0.45) | FGFR1KDRPDGFRBEGFRFLT3 | |
| SCHEMBL2114116 | 0.78 | LRRK2 (0.42) | FGFR1KDRPDGFRBEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | FGFR1 462/4885KDR 395/4885PDGFRB 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.